OUR RESEARCH DIRECTION

혈관 기능 정상화를 통한 새로운 치료 가능성 제시

큐라클은 ‘혈관 기능 정상화’라는 독창적인 접근으로 난치성·노인성 질환의 새로운 치료 가능성을 제시하며, 망막·신장·혈전성 질환을 중심으로 다양한 혈관 관련 질환으로 연구 영역을 넓혀가고 있습니다.

망막질환

혈관 안정화와 기능 회복을 통한 시력 보호

신장질환

혈관 보호와 염증·섬유화 조절을 통한 신장 기능 보존

혈전·허혈성 질환

출혈 위험 최소화를 추구하는 항혈전 접근과 혈관 보호

Main Pipelines

Pipeline Modality Target Indication Development Status Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU06
(Rivasterat) 		PO Endothelial Dysfunction Blocker Diabetic Macular Edema / Age-related Macular Degeneration Completed Phase 2a clinical trial in the U.S. (Q1 2024)
CU01 PO NRF2 / TGF-β Diabetic Nephropathy Completed Phase 2b clinical trial in Korea (Q1 2026)
MT-101 IV (mAb) Tie2 Acute Kidney Injury/ Chronic Kidney Disease Preclinical studies in progress
MT-103
(MMT-205) 		IV (BsAb) Tie2 / VEGF Diabetic Macular Edema / Age-related Macular Degeneration Global licensing to Memento Medicines (May 2026).
Preclinical studies in progress
MT-201 IV (mAb) PDI Thrombotic Diseases Preclinical studies in progress
MT-202 IV (BsAb) PDI / Tie2 Thrombotic Diseases Preclinical studies in progress

Emerging Pipelines

Pipeline Modality Target Indication Development Status Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU71 PO Endothelial Dysfunction Blocker Neurodegenerative Disease Discovery
CU72 PO Undisclosed Idiopathic Pulmonary Fibrosis Discovery
CU73 PO Undisclosed Thrombotic Diseases Discovery
CU03 PO Multi Target Age-related Macular Degeneration Completed Phase 2a clinical trial in Korea (Q1 2022)
CU104 PO Indication expansion of CU06 Ulcerative Colitis Completed Phase 1 clinical trial in the U.S.
CU106 PO Indication expansion of CU06 Immuno-Oncology Combination Completed Phase 1 clinical trial in the U.S.
MT-105 IV Undisclosed Inflammatory Bowel Disease Discovery
MT-40X IV Undisclosed Cancer Discovery
MT-501 IV (BsAb) Tie2 / C5 axis Vasculitis Discovery
CP01 PO Endothelial Dysfunction Blocker Kidney Failure in Companion Animals Phase 3 clinical trial in dogs ongoing (Korea)